Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 4,564 $ 4,929
Amortization of intangible assets 380
General and administrative expenses 1,644 2,477
Operating loss 6,208 7,786
Other income (91)
Interest expenses 565 461
Finance income, net (327) (87)
Loss before tax 6,355 8,160
Tax expenses 6 9
Net loss $ 6,361 $ 8,169
Basic and diluted loss per share of Common Stock (in Dollars per share) $ 0.2 $ 0.27
Weighted average number of shares of Common Stock outstanding, basic and diluted (in Shares) 32,125,227 29,754,240